{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:06:12Z","timestamp":1790697972495,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Peptide receptor radionuclide therapy (PRRT) can cause dose-limiting toxicities (DLTs) of the bone marrow, liver, and kidneys. It is yet unknown whether women and men are equally at risk of these DLTs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Neuroendocrine tumor patients treated with <jats:sup>177<\/jats:sup>Lu-DOTATATE between 2000 and 2015 in our phase II trial with available laboratory data were included. For all DLTs, the highest Common Terminology Criteria for Adverse Events (version 4.03) grades that occurred from the start of PRRT until 3 months after the last cycle were scored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>At baseline, women (n = 439) had a significantly lower body mass index, Karnofsky Performance Score, hemoglobin level, and creatinine clearance and a significantly higher platelet level than men (n = 534). Both groups received a median activity of 29.6 GBq (800 mCi). After the start of PRRT, women more frequently developed grade \u22652 thrombocytopenia compared with men (25% vs 18%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.004) due to a significant increase in grade \u22653 thrombocytopenia (11% vs 6%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.008). Furthermore, the incidence of grade \u22653 anemia was higher in women (7% vs 3%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.002). In the multivariable regression model, female sex (odds ratio, 2.50; 95% confidence interval, 1.67\u20133.74) was confirmed to be an independent risk factor for grade \u22652 thrombocytopenia, among baseline platelet count, bone metastases, uptake on <jats:sup>111<\/jats:sup>In-DTPA-octreotide scan, Karnofsky Performance Score, alkaline phosphatase, lymphocytes, albumin, and renal function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Female neuroendocrine tumor patients more often experienced PRRT-induced toxicities of platelets and hemoglobin than males, but this did not lead to a lower cumulative activity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004203","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T16:00:08Z","timestamp":1650038408000},"page":"599-605","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Dose-Limiting Bone Marrow Toxicities After Peptide Receptor Radionuclide Therapy Are More Prevalent in Women Than in Men"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1758-0163","authenticated-orcid":false,"given":"No\u00e9mie S.","family":"Minczeles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Konijnenberg","sequence":"additional","affiliation":[{"name":"Department of Radiology & Nuclear Medicine, ENETS Centre of Excellence, Erasmus MC and Erasmus MC Cancer Centre, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Brabander","sequence":"additional","affiliation":[{"name":"Department of Radiology & Nuclear Medicine, ENETS Centre of Excellence, Erasmus MC and Erasmus MC Cancer Centre, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Hofland","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-DOTATATE for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","year":"2017","journal-title":"Clin Cancer Res"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib4-20250621","first-page":"593","article-title":"Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"27","year":"2012","journal-title":"Cancer Biother Radiopharm"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MNM.0000000000000795","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival","volume":"39","year":"2018","journal-title":"Nucl Med Commun"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","article-title":"Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"54","year":"2013","journal-title":"J Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-016-3533-z","article-title":"Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with (177)Lu-D OTATATE","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00259-015-3001-1","article-title":"Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/RLU.0000000000001629","article-title":"Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with somatostatin receptor expressing neuroendocrine tumors: six years\u2019 assessment","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"e212274","DOI":"10.1001\/jamanetworkopen.2021.2274","article-title":"Laboratory, clinical, and survival outcomes associated with peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors","volume":"4","year":"2021","journal-title":"JAMA Netw Open"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00259-014-2735-5","article-title":"177Lu-DOTA-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00259-013-2601-x","article-title":"Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.nucmedbio.2019.08.005","article-title":"Sex-differences in [68Ga]Ga-DOTANOC biodistribution","volume":"76-77","year":"2019","journal-title":"Nucl Med Biol"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","article-title":"Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"e19304","DOI":"10.1097\/MD.0000000000019304","article-title":"The therapeutic efficacy of 177Lu-DOTATATE\/DOTATOC in advanced neuroendocrine tumors: a meta-analysis","volume":"99","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2967\/jnumed.112.107524","article-title":"Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment","volume":"54","year":"2013","journal-title":"J Nucl Med"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40658-016-0157-0","article-title":"A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity","volume":"3","year":"2016","journal-title":"EJNMMI Phys"},{"key":"bib21-20250621","first-page":"406","article-title":"Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC","volume":"22","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejmp.2018.11.001","article-title":"A dosimetry procedure for organs-at-risk in (177)Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours","volume":"56","year":"2018","journal-title":"Phys Med"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13550-018-0459-4","article-title":"Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using 177Lu-[DOTA0, Tyr3]-octreotate","volume":"8","year":"2018","journal-title":"EJNMMI Res"},{"issue":"supplement 1","key":"bib24-20250621","article-title":"Is there a gender difference of absorbed dose to the risk organs in patients receiving 177Lu-octreotate therapy?","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cpet.2020.12.011","article-title":"Somatostatin receptor imaging PET in neuroendocrine neoplasm","volume":"16","year":"2021","journal-title":"PET Clin"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","article-title":"Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate","volume":"36","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2967\/jnumed.115.165803","article-title":"68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","article-title":"Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2967\/jnumed.118.225235","article-title":"Bone marrow absorbed doses and correlations with hematologic response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s00259-017-3688-2","article-title":"Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40658-016-0153-4","article-title":"Radiation exposure of the spleen during (177)Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume","volume":"3","year":"2016","journal-title":"EJNMMI Phys"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/978-3-642-27994-2_33","article-title":"Is there a correlation between peptide receptor radionuclide therapy\u2013associated hematological toxicity and spleen dose?","volume":"194","year":"2013","journal-title":"Recent Results Cancer Res"},{"key":"bib34-20250621","first-page":"29","article-title":"Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms","volume":"20","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"bib35-20250621","first-page":"e929590","article-title":"Effect of 131I therapy on complete blood count in patients with differentiated thyroid cancer","volume":"27","year":"2021","journal-title":"Med Sci Monit"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"e4451","DOI":"10.1097\/MD.0000000000004451","article-title":"Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer","volume":"95","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1210\/jc.2015-2124","article-title":"Bone marrow function after (131)I therapy in patients with differentiated thyroid carcinoma","volume":"100","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"102881","DOI":"10.1016\/j.critrevonc.2020.102881","article-title":"Gender-dependent radiotherapy: the next step in personalised medicine?","volume":"147","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.mehy.2011.08.021","article-title":"Interaction between ionizing radiation and estrogen: what we are missing?","volume":"77","year":"2011","journal-title":"Med Hypotheses"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/09553002.2020.1741720","article-title":"The radiotherapy cancer patient: female inclusive, but male dominated","volume":"96","year":"2020","journal-title":"Int J Radiat Biol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:00:51Z","timestamp":1750536051000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004203","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,15]]}}}